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ABSTRACT
Objective: To examine neurocognitive impairment (NCI) and its association with antiretroviral
therapy (ART) medication adherence among HIV-infected men who have sex with men (MSM)
and transgender women (TGW) in Lima, Peru.
Methods: A cross-sectional survey assessed 313 HIV-infected Peruvian MSM and TGW
prescribed ART using a computer-assisted survey instrument to examine NCI and its association
with optimal ART adherence, defined as taking ≥90% of prescribed medications. The survey
included demographic characteristics and standardized measures for drug and alcohol use
disorders, depression, and other factors associated with non-adherence.
Results: An exploratory factor analysis was conducted to optimize an NCI self-report scale for
use with HIV-infected MSM and TGW in Peru. Participant scores indicated moderate NCI and
131 (41.7%) and 134 (42.5%) participants met criteria for an alcohol use disorder (AUD) or
depression, respectively, 33 (10.5%) reported recent recreational drug use, and 81 (26.3%) had
low health literacy. Overall, 268 (85.9%) met criteria for self-reported optimal ART adherence.
Psychomotor NCI subscale score (AOR=0.534; 95% CI=0.317-0.931), having an AUD
(AOR=0.203; 95% CI=0.063-0.655), identifying as transgender (AOR=0.175 95% CI=0.0320.954), and low health literacy (AOR=0.253 95% CI=0.077-0.831) were independently and
negatively correlated with optimal ART adherence. Income of minimum wage or higher was
independently and positively correlated with optimal ART adherence. Depression was significant
only in the bivariate analysis, but did not remain significant after controlling for other covariates.
Conclusions: NCI is prevalent among Peruvian HIV-infected MSM and TGW and psychomotor
impairment is independently correlated with suboptimal ART adherence. Our findings support
the need to screen and treat or accommodate NCI in order to improve ART adherence among
HIV-infected MSM/TGW.
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Table 1: Characteristics of HIV-infected men who have sex with men and transgender women
on antiretroviral therapy in Lima, Peru (N=313)
Characteristic

N = 313 (%)

Median Age, years (S.D.)

34.3 (± 8.2)

Completed Secondary school
No
Yes

97 (30.9)
217 (69.1)

Monthly Income
None
Less than minimum wage
Minimum wage or greater

38 (12.1)
94 (30.0)
181 (57.8)

Sexual Orientation (self-identified)
Homosexual (gay)
Bisexual
Heterosexual

246 (78.3)
55 (17.5)
13 (4.2)

Transgender
No
Yes

282 (93.4)
20 (6.6)

Living Situation
Alone
With sexual partner
With family or nonsexual partner

57 (18.2)
50 (15.9)
207 (65.9)

Occupation
Full-time
Part-time
Unemployed

163 (51.9)
82 (26.1)
69 (22.0)

Adherence Facilitators
Using an alarm clock
Taking ART with other medications
Placing ART in sight
Associating taking ART with sleeping or awakening
Placing ART in the same location
Using post-it notes or other paper reminders
Using a calendar
Associating taking ART with eating
Asking a family member or friend for a reminder
Multiple reminders

N = 211 (%)
90 (42.8)
2 (0.9)
32 (15.2)
38 (18.0)
11 (5.2)
6 (2.8)
2 (0.9)
29 (13.7)
1 (0.5)
105 (38.3)
1

Neurocognitive Impairment
Mean t-score (S.D.)
Global Impairment
Memory
Frustration Tolerance
Learning
Attention
Pain
Language
Psychomotor

8.8 (±7.7)
5.2 (±4.0)
4.6 (±3.6)
3.5 (±2.6)
1.8 (±1.4)
1.6 (±1.9)
0.9 (±1.4)
0.5 (±1.2)

Alcohol Use Disorders
No alcohol use disorder
Any alcohol use disorder
Hazardous drinking
Harmful drinking
Dependent drinking

183 (58.3)
131 (41.7)
102 (32.5)
18 (5.7)
11 (3.5)

Drug Use in the past 12 months
No
Yes

282 (89.5)
33 (10.5)

Depression
No
Yes

181 (57.5)
134 (42.5)

Health Literacy Issues
No
Yes

227 (73.7)
81 (26.3)

HIV-related Stigma
Mean t-score (S.D.)
Personalized Stigma
Disclosure Stigma
Negative Self-Image Stigma
Public Attitudes Stigma

22.4 (±6.2)
8.5 (±3.2)
6.6 (±1.8)
5.0 (±2.4)
5.2 (±1.9)

Participants on ART
Adherence ≥ 90% (optimal)
Adherence = 100% (perfect)
Mean adherence

N = 313 (%)
268 (85.9)
170 (54.5)
91.1%

Legend: SD=standard deviation; ART=antiretroviral therapy;
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Table 2: Descriptive statistics (Revised NIS)
NIS Subscale
GLOB
MEMR
FRUS
PSYP
LERN
LANG
PAIN
ATTN

N
313
313
313
313
313
313
313
313

Minimum
0
0
0
0
0
0
0
0

Maximum
49
20
19
12
12
7
12
8

Mean
8.84
5.17
4.64
0.49
3.51
0.91
1.57
1.79

SD
7.73
3.96
3.59
1.23
2.60
1.42
1.87
1.38

Legend: GLOB = global impairment; MEMR = memory; FRUS = frustration tolerance; PSYP =
psychomotor; LERN = learning; LANG = language; PAIN = pain; ATTN = attention

3

Table 3: Correlates Associated with Optimal (≥90%) Antiretroviral Therapy Adherence
Among HIV-infected Peruvian Men Who Have Sex with Men and Transgender Women
(N=313)
Covariates

Optimal (≥90%) Antiretroviral Therapy Adherence
Bivariate Associations
Multivariate Associations
OR
AOR
p-value
p-value
(95% CI)
(95% CI)

Neurocognitive Impairment
Global Impairment
Memory
Frustration Tolerance
Learning
Attention
Pain
Language
Psychomotor

0.966 (0.931
– 1.003)
0.956 (0.927
– 0.985)
0.913 (0.844
– 0.989)
0.945 (0.841
– 1.063)
0.940 (0.751
– 1.176)
0.936 (0.800
– 1.094)
0.854 (0.700
– 1.042)
0.795 (0.647
– 0.978)

0.068

_

_

0.114

–

–

0.026

0.884 (0.769 –
1.017)

0.085

0.349

–

–

0.587

–

–

0.405

–

–

0.119

–

–

0.030

0.534 (0.317 –
0.931)

0.026

Alcohol Use Disorders

0.399 (0.207
– 0.768)

0.006

0.203 (0.063 –
0.655)

0.008

Transgender Women

0.386 (0.130
– 1.144)

0.086

0.175 (0.032 –
0.954)

0.044

Health Literacy

0.859 (0.685
– 1.078)

0.191

0.253 (0.077 –
0.831)

0.024

HIV-related Stigma

1.041 (0.984
– 1.101)

0.162

–

–

0.057

–

–

0.809

–

–

0.788

–

–

Initiation/Completion of
Higher Education
CD4 Nadir
Time since HIV Diagnosis

1.885 (0.982
– 3.620)
1.000 (0.998
– 1.001)
0.989 (0.916
– 1.069)
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Age

1.020 (9.80 –
1.062)

0.324

–

–

Earned minimal wage or
greater

2.758 (1.375
– 5.535)

0.004

3.037 (1.016 –
9.081)

0.047

Living Alone

0.688 (0.276
– 1.717)

0.423

–

–

Full-time Employment
(stable)

1.460 (0.748
– 2.849)

0.267

–

–

Depression

0.918 (0.864
– 0.975)

0.005

–

–

Drug Use in Previous 12
Months

0.939 (0.750
– 1.175)

0.581

–

–

Domestic Violence in Past 12
Months

0.939 (8.29 –
1.062)

0.316

–

–

Adherence Facilitators*

1.134 (0.630
– 2.041)

0.676

–

–

–

–

3.789 (1.085 –
13.237)

0.037

Food Insecurity
Any

1.401 (0.720
– 2.728)

0.321

Hunger

1.186 (4.98 –
2.825)

0.700
Log
Likelihood =
90.931

Legend: OR = Odds Ratio; AOR=Adjusted Odds Ratio; *An adherence facilitator is any cue or
reminder that a participant regularly used to aid him or her with medication-taking.
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Supplementary Table: Factor loadings from exploratory factor analysis of the original NIS
Factor/Label
Items

1
GLO
B
.692

2
ME
MR
.241

I have trouble remembering.

.613

.185

.178

.337

.104

.120

.007

.152

My judgment is poor.

.581

.207

.238

.161

.132

.172

.026

.096

My mind is dull

.556

.113

.261

.213

.024

.196

.008

.103

Something is wrong with my mind.

.538

.108

.190

.085

.168

.162

.201

-.002

I do things slowly.

.535

.088

.062

.032

.145

.067

.153

.048

My mind works slowly

.534

.344

.096

.112

.105

.073

.084

-.075

My brain becomes tired easily.

.529

.293

.233

.317

.024

.034

.098

.144

I have trouble remembering important
things.
I have trouble concentrating.

.500

.399

.168

.116

.089

.175

.104

.136

.494

.441

.165

.266

.216

.079

.065

.307

I get confused easily.

.489

.476

.160

.049

.197

.236

.128

.159

I forget what I read.

.488

.319

.154

.088

.110

.162

.186

.222

I have trouble writing sentences.

.476

.294

.140

.244

-.075

.188

-.047

-.038

My mind won’t stay on any one thing.

.423

.190

.220

.027

.077

.084

.168

.289

My mind tends to wander.

.411

.127

.172

.053

.159

.292

.259

.142

I forget where I put things.

.126

.708

.150

.005

.155

.092

.059

.124

I am forgetful

.190

.680

.086

.048

.069

.054

.081

-.021

My reactions are slow.

3
4
FRU
PSYP
S
.117
.075

5
LER
N
.197

6
7
LAN
PAIN
G
.111
.156

8
ATT
N
.199

6

I have serious memory problems.

.331

.585

.015

.051

-.005

.154

.215

.030

I often lose things.

.320

.571

.109

.089

.093

.174

.129

.181

I have a hard time remembering people’s
names.
I have difficulty paying attention.

.123

.491

.063

.023

.148

.191

.072

.141

.318

.466

.174

.260

.083

.068

.040

.353

My words get mixed up.

.272

.403

.285

.187

.016

.340

.108

.017

I feel easily annoyed and irritable.

.247

-.015

.752

.093

.104

.062

.061

.113

I have a bad temper.

.155

.063

.687

.139

.089

.036

-.037

.029

I get into arguments frequently.

.130

.112

.651

.103

.198

.154

.086

.132

I have urges to break and smash things.

.154

.180

.597

.030

.032

.113

.142

.031

I fall apart under pressure.

.185

.262

.554

.137

.182

.087

.181

.108

Part of my body is paralyzed.

.057

.055

.128

.679

.050

.118

-.008

.121

I fall down sometimes.

.159

.090

.139

.594

-.067

.110

.159

-.010

I have been knocked unconscious.

.126

-.017

.008

.540

.118

.050

.139

.087

I have trouble with the right side of my
body.
Doing simple math problems in my head
is difficult.
My arithmetic is poor.

.358

.113

.141

.488

.053

.115

.100

-.196

.256

.190

.200

.082

.797

.044

.055

.091

.158

.102

.141

-.009

.728

.054

.085

.075

I count with my fingers.

.133

.223

.222

.252

.377

.019

.028

-.014

My speech has become worse.

.264

.311

.140

.124

.027

.689

.071

.019

I have trouble spelling.

.218

.160

.086

.263

.105

.585

.009

.171

I have trouble talking.

.346

.228

.207

.130

-.001

.492

.088

-.011
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I have severe headaches.

.201

.238

.297

.071

.021

.029

.654

.057

I suffer from severe pain.

.270

.257

.301

.137

.040

.007

.550

-.038

I have had a head injury.

.061

.037

-.042

.130

.067

.058

.450

.079

I am easily distracted.

.303

.336

.288

.096

.121

.112

.106

.602

I am absent - minded.

.278

.337

.206

.112

.121

.117

.167

.471

Notes:
EFA excluded: ‘validity scale’ items, items with loadings below 0.40, and items with shared
loadings of equal strength across multiple factors
Total percent of variance = 51.78%
Shaded areas represent the criteria that correspond to each factor
GLOB: Global impairment; MEMR: Memory-related impairment; FRUS: Frustration Tolerancerelated impairment; PSYP: Psychomotor-related impairment; LERN: Learning-related
impairment; LANG: Language-related impairment; PAIN: Pain-related impairment; ATTN:
Attention-related impairment
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INTRODUCTION
The global HIV pandemic affects nearly 35 million people [1] and the various
manifestations of HIV negatively impact the lives of people living with HIV/AIDS (PLWHA).
Even though a cure for HIV remains elusive, HIV has become a chronic disease requiring longterm management to reduce HIV-related morbidity and mortality, which allows PLWHA to have
near-normal lifespans [2-6]. Despite recent increasing antiretroviral treatment (ART) coverage
globally and resultant decreased HIV-related morbidity and mortality [5, 7], the central nervous
system (CNS) is vulnerable to HIV [8]. The presence of HIV in the brain, spinal chord, and
peripheral nerves and its impact on neurological function has been extensively studied [9, 10].
The neurological impact of HIV is now commonly referred to as neurocognitive impairment
(NCI). NCI research among PLWHA has increased recently [11, 12], but many gaps remain in
translating findings into clinical improvement [8].
Using various measurements, NCI is associated with numerous adverse clinical
consequences, including ART non-adherence [6], increased HIV risk-taking behaviors [6, 13],
difficulty in performing daily tasks [14, 15], shorter survival [8, 16], and reduced health-related
quality-of-life [17, 18]. The negative consequences of NCI exacerbate HIV-related symptoms
among PLWHA and increase transmission risk to uninfected partners [19]. ART adherence,
while important for many reasons, is crucial to mitigate the effects of NCI. In the absence of
ART, NCI-related symptoms worsen with HIV disease progression [20] and ART can
significantly decrease NCI-related symptoms [21]. NCI not only impedes PLWHA from
accessing ART, but may also reduce its efficacy through suboptimal ART adherence, thereby
necessitating effective interventions to intervene in PLWHA with NCI.
While the severity of NCI among PLWHA has decreased in recent years, mild NCI is still
prevalent, reaching levels of 50% in some settings [22, 23]. The ability of HIV to penetrate the
9

CNS negatively impacts several neurocognitive domains, including memory, executive
functioning, attention, and psychomotor skills [24, 25], which in turn may impede ART
adherence [26]. The direct association between general NCI and ART nonadherence was
described in the early stages of HIV/AIDS [27]. Several subsequent studies have further
elucidated this relationship, noting deficits in executive function, working memory, and attention
[6, 28, 29]. This is particularly concerning, given the ambitious 90-90-90 target set by UNAIDS.
The goals by 2020 are that 90% of all PLWHA know their HIV status, 90% of all people with
diagnosed HIV infection will receive sustained ART, and 90% of all people receiving ART will
have viral suppression [30]. In order to satisfy the third goal, viral suppression requires optimal
adherence to ART, which is threatened by the presence of NCI.
To date, NCI in PLWHA has yet to be examined in the Latin American context,
especially with regard to ART adherence [31]. In Peru and throughout much of Latin America,
the HIV epidemic remains concentrated among men who have sex with men (MSM) and
transgender women (TGW) [5, 32]. While the overall prevalence of HIV/AIDS in Peru is
reported to be only 0.4% [33] HIV prevalence among MSM is between 18-22% [34] and
approaches 33% in TGW [34, 35]. MSM represent a particularly vulnerable population in Peru,
with HIV prevalence over 100-fold higher in the general population and 20-fold higher than in
other vulnerable populations like in female sex workers [36]. Although Peru is a middle-income
country that provides free ART with coverage exceeding 40% [5], there are currently no
interventions tailored to the MSM community that promote ART adherence.
Given the potential for NCI to be a confounding variable in assessing HIV treatment
outcomes, I sought to investigate the prevalence of NCI among HIV-infected MSM and TGW in
Lima, Peru and characterize other demographic, cultural, and personal barriers to ART
adherence among these two groups. In addition, I sought to determine the association of NCI and
10

these other variables with our outcome variable, ART adherence. I hypothesized that NCI would
be prevalent among HIV-infected MSM and TGW in Lima, Peru. Likewise, NCI, especially
among the most affected individuals, would be associated with decreased ART adherence, which
has remained unexplored among Peruvian MSM and TGW.
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LITERATURE REVIEW OF RELEVANT STUDIES
HIV/AIDS in Peru
In the 1980s and early 1990s, Peru was in a state of significant political turmoil. Since
then, the country’s economic conditions have improved in some ways, but remains bleak in
others. For example, over 50% of Peru’s population is estimated to be poor with about 25%
living in extreme poverty. The health, education, legal, and other government sectors remain
weak with suboptimal investment compared to sectors in other Latin American countries. These
political and economic factors have played a large role in shaping the nation’s HIV/AIDS
epidemic [37]. UNAIDS reported the following country estimates in 2014: [A] 0.4% prevalence
rate among 15-49 year olds; [B] 72,000 individuals living with HIV; [C] 21,000 women aged 15
and up living with HIV; [D] 2,200 children aged 0 to 14 years living with HIV; and [E] 2,500
deaths due to AIDS in 2014 [38]. While this information is useful for understanding the
HIV/AIDS epidemic in the total population, these numbers mask the true nature of the epidemic.
Since the first case was reported in 1983, the Peruvian HIV epidemic has been concentrated in
vulnerable communities, specifically among MSM. HIV prevalence among MSM has
consistently been above 10% in Lima, Peru in comparison to 1% among pregnant women and
female sex workers – other traditionally vulnerable communities. Since 75% of Peruvians live in
urban centers, the HIV epidemic is considered to be an urban issue and most cases are on the
coastline or in rain forest regions of Peru. While it initially affected the wealthier segments of
society, it quickly spread through the poorer communities [39].
Lima, the capital of Peru, has been the epicenter of innovative research and program
implementation. From 1996 to 2002, HIV prevalence among MSM increased from 18.5% to
22.3% in Lima [40], suggesting that MSM in Lima constitute an important target population for
intensified and innovative biomedical intervention, such as HSV-2 suppression, pre-exposure
12

chemoprophylaxis, HIV vaccines, and male circumcision [34]. HIV infection in this group has
been associated with gay sexual orientation, high-risk sexual behaviors, drug and alcohol use,
and other sexually transmitted infections (STIs) [41]. In a recent study, over 5,000 sexually
active MSM were recruited to participate in a cross-sectional bio-behavioral study to better
understand if these risk behaviors are mediated by the disinhibiting use of alcohol and other
drugs. The authors found that the majority of participants (62.8%) met screening criteria for
alcohol use disorders (AUDs) which were also independently associated with several high-risk
sexual risk behaviors previously found to be associated with HIV transmission [42]. Because the
HIV continuum of care includes several steps – including HIV diagnosis, linkage to and
retention in HIV care, initiation and adherence with ART, and viral suppression – another study
sought to address factors associated with suboptimal HIV treatment engagement and ART
adherence. Of the 302 participants recruited, the prevalence of AUDs was 43.2% while 87.1%
reported optimal adherence (defined as taking 90% or more of prescribed medications) and 55%
reported perfect adherence (defined as taking all prescribed medications). AUDs were highly
prevalent among the Peruvian HIV-infected MSM participants in the study and AUDs
contributed significantly to suboptimal ART adherence. These findings further support the
necessity of screening for and treating underlying AUDs [43].
HIV Medication Adherence
Since 1996, there has been an overwhelming amount of evidence supporting the use of
antiretroviral therapy (ART) for the treatment of HIV/AIDS. Optimal ART adherence is
associated with viral load suppression [44-46], improved quality of life [47, 48], longer survival
[49], and decreased risk of transmitting HIV to others [50, 51], and reduced risk of developing
resistance to HIV medications [52, 53].
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One of the earliest and largest breakthroughs in the field of HIV/AIDS was the efficacy
of triple-combination therapy in suppressing HIV viral load in PLWHA to non-detectable levels.
One landmark study featured 97 HIV-infected patients who were assigned to one of three
treatment groups: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours
combined with 150 mg of lamivudine twice daily; or all three drugs. The decrease in HIV RNA
over the first 24 weeks was significantly greater in the three-drug group compared to the other
two groups and these results persisted up to the completion of the study (52 weeks). Therefore,
the triple combination of indinavir, zidovudine, and lamivudine was a more effective treatment
regime compared to these drugs separately or in dual combination [45].
The importance of adherence to ART is far more than the reduction of viral load and
increase in immunological function in HIV-infected individuals. It also contributes to better
overall health. In one study, 98 HIV-infected individuals in Central China were asked to selfreport their ART adherence and had their quality of life (QoL) assessed using SF-36, a validated
scale for measuring QoL. Of the total participants, 58% reported taking all their prescribed
medications and were classified as consistent adherers. These individuals had better physical
function, general health, vitality, social functioning, mental health, presented a higher CD4 cell
count, and had overall lower healthcare costs [47]. Another study examined 1050 HIV-infected
participants in two large, randomized, clinical trials. Adherence to ART was self-reported and
QoL was assessed using the SF-12, as shorter version of the aforementioned SF-36. Individuals
that reported 100% ART adherence achieved significantly higher QOL life scores as compared
to those with poorer adherence. Those with at least 80% ART adherence had smaller but still
significant increases in QoL, while those with less than 80% adherence reported worse QoL [48].
Optimal ART adherence has also been associated with higher survival rates and lower
mortality. One team enrolled 6288 individuals, 52% of whom had adherence greater than or
14

equal to 80% and 30% of whom had perfect adherence. These authors showed that adherence of
less than 80% was associated with lower survival. Medication adherence was also divided into 5
strata, each with a width of 20%; each stratum had lower survival rates than the next, higheradherence stratum [49]. Finally, access and adherence to ART is associated with a decreased risk
of HIV transmission. The landmark HPTN 052 study evaluated the effect of early vs. delayed
ART on the prevention of HIV-1 transmission from an HIV-infected individual to their
uninfected partners. Using pill counts, optimal adherence (defined as taking greater than or equal
to 95% of medications) to the study regimen was observed in 79% of participants in the earlytherapy group and 74% of those in the delayed-therapy group. Among the 1763 serodiscordant
couples enrolled, there was a relative reduction of 96% in the number of linked HIV-1
transmissions in the early ART group as compared to the delayed ART group [50]. In another
landmark prospective cohort study, researchers followed 16,667 individual who were HIVuninfected and observed individual HIV seroconversions from 2004 to 2011. The authors found
that the risk of individual HIV acquisition declined significantly with increasing ART coverage
in the surrounding community when holding other key HIV risk factors constant. For example,
an uninfected individual living in an area with 30-40% ART coverage was 38% less likely to
acquire HIV as compared to someone living in a community with less than 10% ART coverage
[51].
While optimal ART adherence provides a multitude of benefits, it is imperative to note
the negative consequences of suboptimal adherence to ART, such as drug resistance. For HIVinfected individuals, drug resistance is a major concern. The relationship has been described to
look “bell shaped” where the two extremes – total non-adherence and complete adherence – are
associated with low probabilities of drug resistance, whereas intermediate levels of adherence
increase the risk of drug resistance [52]. Another study quantified the risk factors associated with
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drug resistance. The authors found that a cumulative adherence of 70%-89%, a CD4+ cell nadir
of <200 cells/ul, and the missing of a scheduled clinic visit in the past month were all
independently associated with increased hazard of viral rebound [53]. Therefore, clinicians and
patients should set high adherence goals to avoid the development of drug resistance.
Barriers to HIV Medication Adherence
The aforementioned studies present invaluable examples of the benefits of optimal ART
adherence. While these are goals that individuals and health systems should strive to meet, there
are also a multitude of barriers that prohibit optimal adherence to ART. Depression is one serious
barrier that has garnered attention and has been linked to poor health outcomes. One metaanalysis examined the relationship between depression and HIV medication non-adherence.
Depression was associated with non-adherence across 95 independent samples, which was
consistent over time and was not inflated by self-report bias [54]. Conversely, another study
sought to determine whether antidepressant medication treatment increases the probability of
HIV viral suppression. Among 158 homeless and marginally housed individuals living with HIV,
there were 2.03 greater odds of achieving viral suppression when taking antidepressant
medication treatment. Self-reported adherence to ART increased by 25% and the odds of
reporting complete adherence nearly doubled [55]. Both of these studies suggest that
interventions aimed at reducing depressive symptom severity should be explored to increase
ART adherence among HIV-infected individuals.
Substance abuse is another barrier worth considering when dealing with HIV medication
adherence. An early study examined the impact of ongoing drug use on ART adherence and viral
suppression. The authors studied 85 HIV-infected current and former drug users and found that
several variables were associated with poor adherence, including active cocaine use and the
tendency to use alcohol or drugs to cope with stress. The strongest predictor of poor adherence
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and the failure to maintain viral suppression was active cocaine use. Overall, adherence among
active cocaine users was much lower (27%) as compared to subjects who reported no cocaine
use during the 6-month study period (68%). Furthermore, only 13% of the former group
maintained viral suppression as compared to 46% of the latter group [56]. Another longitudinal
study examined the impact of drug use on medication adherence among 150 HIV-infected
individuals, 102 of who reported recent illicit drug use. Not only did drug-positive individuals
have worse medication adherence than drug-negative participants (63% vs. 79%, respectively), a
logistic regression model showed that drug use was associated with over a four-fold greater risk
of adherence failure. The authors concluded that stimulant users were at greatest risk for poor
adherence [57]. While historically a great deal of attention on substance abuse has been directed
at drug use, alcohol has emerged as a new focus of research. Alcohol use has been cited as a
factor in non-adherence to ART. One meta-analysis aggregated findings across numerous studies
to provide a quantitative evaluation of the alcohol-adherence association. In the combined
analysis, alcohol drinkers were about 50% less likely to be adherent to ART as compared to
those who abstained from drinking [58]. Another meta-analysis found similar results. Forty-one
studies were included in the aggregate analyses to examine AUDs and ART adherence. These
findings consistently support an association between AUDs and decreased adherence to ART and
poor HIV treatment outcomes among HIV-infected individuals [59].
While HIV is a devastating biological agent that has revolutionized pharmaceutical
research and medicine, the virus has also had a tremendous effect on social issues around the
world. HIV largely affects the most marginalized communities, which have suffered from the
virus itself and conservative social norms. Insight into the effects of social support has helped
explain how social interactions could mediate adherence to ART. One early study examined 205
HIV-infected prisoners and details social desirability and trust in members of the medical field
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and society at large. While adherence to ART was relatively high (84%) among this group of
prisoners, the researchers found that social isolation was associated with decreased adherence to
medications. Trust and the therapeutic relationship between the patient and physician remain
central in the ART initiation process [60]. Another cross-sectional survey in Thailand analyzed
patients on ART to examine barriers to adherence. Based on logistic regression analysis, HIV
disclosure and family communication were among the significant predictors of adherence. While
both of these variables were reported to play important positive roles [61], is it also worth
examining the deleterious effects of stigma and discrimination on ART adherence among HIVinfected individuals. In one study, 202 HIV-infected participants in Los Angeles County were
asked to self-report HIV stigma, access to medical care, and adherence to ART. About one-third
of participants reported high levels of stigma and only 57.5% reported optimal ART adherence.
In unadjusted analyses, those who reported high level of stigma were more likely to report poor
access to care and lower ART adherence. Mental health was reported to mediate the relationship
between stigma and ART adherence [62]. In another study, 204 HIV-infected patients in two
Chicago hospital sites were recruited to determine the threat of social stigma. The authors found
that people with high HIV stigma concerns were 2.5 times less likely to interpret the meaning of
CD4 count correctly and 3.3 times more likely to be nonadherent to their medication regime as
compared to those with low stigma concerns. In the multivariate analyses, concern over
revealing HIV status was the only statistically significant, independent predictor of adherence
[63]. The aforementioned research suggests that reducing stigma and discrimination among HIVinfected individuals would help improve treatment outcomes.
Neurocognitive Impairment
Over thirty years have passed since HIV emerged as a major challenge to health and
united the scientific community worldwide to combat its devastating impact. While HIV has
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largely been recognized for its deleterious effects on the cellular immune system, it has also had
broad impact on the human nervous system. Over the years, research has elucidated HIV’s
pathology in the brain, spinal chord, and peripheral nerves, which has deeply impacted
neurological function in a variety of ways. This neurological involvement of HIV is now
commonly referred to as neurocognitive impairment (NCI).

Until the introduction of

combination ART in the mid-1990s, HIV-1 associated dementia (HAD) and other cognitive
disorders affected 20-30% of patients with advanced immunosuppression or AIDS. Although
combination ART dramatically reduced these severe manifestations of NCI, mild to moderate
NCI exists in a significant portion of patients some of who are virally suppressed [9, 10, 64].
As with some other lentiviruses, HIV enters into the central nervous system (CNS) due to
infection of the human immune cells. One of these host cells, monocytes, have been described as
“Trojan horses” because they readily enter the CNS, bringing along HIV that replicates
effectively in these cells [65]. In addition, HIV is brought into the CNS by lymphocytes, which
can harbor viruses that replicated in macrophages or as free virions where the means of entry
would be through endothelial cells [9]. Research has demonstrated that the virus is present in the
cerebral spinal fluid (CSF) at early stages of HIV infection, including in patients diagnosed with
primary infection [66]. While it is not certain how this manifestation affects HIV found in the
brain, studies have shown that long-term HIV infection leads to genetically isolated populations
of virus in the CNS [67, 68].
While research is ongoing to better characterize the impact of HIV on neurocognitive
functioning, there is clear evidence suggesting the importance of ART adherence in minimizing
NCI among HIV-infected individuals. It is worth noting that several other phrases have been
used

to

describe

HIV-related

neurocognitive

impairment,

including

HIV-associated

neurocognitive disorders (HAND) [69] and HIV-associated dementia (HAD) [26]. A recent
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study assessed the cognitive outcomes of 111 HIV-infected patients with varying levels of
cognitive outcomes before beginning ART and compared these results after being on ART for
one year. There was clear evidence that participants on ART had similar or improved cognitive
function results after one year compared to those who were not on ART [70]. Another study
sought to describe the prevalence of NCI among HIV-infected individuals who were diagnosed
and clinically managed early and compare their neurological functioning to HIV-uninfected
controls. The study concluded that HIV-infected patients who were diagnosed and managed
early during the course of their HIV infection had a low prevalence of NCI, which was
comparable to matched HIV-uninfected individuals. Early recognition and management of HIV
infection may be important in limiting neurocognitive impairment [21]. Lastly, an early study of
NCI found that patients with poor neuropsychological scores reduced from 81% to 50% and then
to 22% following 6 and 15 months of ART, respectively. Prevalence of impaired memory was
also reduced from 50% to 9% after 15 months of taking HIV medications [71]. In the absence of
ART, NCI-related symptoms have been shown to worse with HIV disease progression. One
study examining the neurocognitive functioning and brain magnetic resonance imaging in 389
HIV-infected individuals and 111 uninfected controls found increased rates of impairment at
each successive stage of HIV infection. Impairment in HIV-infected subjects was related to
central brain atrophy on MRI results as well as to evidence of cellular immune activation and
neurological abnormalities linked to the central nervous system [20].
Using various measurements, NCI has been associated with numerous adverse clinical
consequences. One study explored the nature of NCI caused by HIV and suggests that it plays a
role in increased risk-taking behavior. Impaired executive function prevents rational decisionmaking by inhibiting the consideration of future outcomes, which may result in making unsafe
sexual choices. In addition, reduced speed of information processing or reaction time may also
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play a role in increasing risk. Impulse control may also be impaired in individuals suffering from
HIV-associated NCI due to effects of HIV, substance abuse, or underlying mental illness, which
could increase HIV risk behaviors [6].

NCI has also been associated with difficulty in

performing daily tasks and higher risk of work disability. A prospective cohort study of gay and
bisexual men examined the incidence of work disability related to the onset of NCI. Compared to
HIV-uninfected individuals, asymptomatic HIV-infected participants were found to have almost
three times the risk of reporting work disability and difficulty performing general tasks [15].
Negative effects of NCI on QoL and decreased neurological functioning has lead to examination
of the effect of NCI on survival. In one study, 1,651 HIV-infected patients were assessed for
neurologic disorders, 24.5% of which had one or more neurologic disorders. Those individuals
with one or more neurologic disorders had higher mortality rates and AIDS-related deaths as
compared to those without neurologic disorders [72].
Research has highlighted that NCI is associated with several adverse outcomes among
HIV-infected individuals with underlying substance use disorders. For example, one study
concluded that 50% to 80% of individuals with AUDs experience mild to severe neurocognitive
impairment. Alcohol use has been linked to physiological and behavioral changes in the CNS,
such as physical damage to the brain and personality disorders, respectively [73]. Individuals
with opioid dependence and abuse demonstrate deficits in attention, working memory, episodic
memory, and executive function during active use. These deficits have been shown to continue
into periods of early abstinence and executive function did not show signs of improvements
during abstinence [74]. Similarly, chronic cocaine users are at greater risk of NCI. Cocaine use
exacerbates HIV replication by increasing the permeability of the blood-brain barrier and
promoting cellular apoptosis [75]. Chronic cocaine users also have impaired executive function,
learning, information-processing speed, memory, attention, and other issues [6, 76].
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Given the goals of this thesis, it is worth understanding some literature findings on the
inverse relationship between neurocognitive impairment and ART adherence. That is, increasing
severity of NCI has been associated with poorer medication adherence. One article reviewed
studies that have investigated the neuropsychological effects of ART for HIV-1 infection and
found that, while ART reduces the prevalence of severe NCI manifestations, mild NCI is still
prevalent. Mild NCI has been associated with poor CNS penetration of some antiretroviral drugs,
drug resistance, and poor adherence [26]. Another study of adherence examined the extent to
which neuropsychological compromise and medication regimen complexity are predictive of
poor adherence in a convenience sample of 137 HIV-infected adults. Both NCI and complex
regimens were associated with lower adherence rates, with cognitively impaired individuals on
complex regimens having the lowest adherence rates. NCI associated manifestations – such as
deficits in executive function, memory, and attention – were associated with 2.3 times greater
risk of adherence failure [27]. Research done in older HIV-infected individuals, normally an age
group with higher medication adherence, also found that NCI was associated with lower
medication adherence. It is possible that there is a vicious cycle of bidirectional influence, where
poor adherence results in NCI and NCI may contribute to lower medication adherence [14].
Assessing Medication Adherence and NCI
While there is no gold standard for assessing adherence among PLWHA [77], several
tools have been implemented over the years. One popular method is self-report of ART
adherence using the visual analog scale. The VAS is simple and quick to administer which
makes it an attractive tool for research and routine patient care [78]. Despite these benefits, selfreport measurements should be properly and carefully assessed as patients may overestimate
adherence. Because various factors may influence patients’ responses, including phrasing of the
question or the doctor-patient relationship, it is imperative that self-report adherence
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measurements are simple, nonjudgmental, routine, and structured [79]. One solution for
minimizing reporting bias in self-report measures is to use Audio Computer-Assisted Self
Interview (ACASI). Participants enter their responses privately into a computer, which makes it
more likely that these individuals will provide honest responses [80]. Other methods for
measuring ART adherence include medication event monitoring system (MEMS) [81], pharmacy
records [82], and pill counts [83].
There are several instruments used to measure NCI, including the HIV Dementia Scale
[84], Grooved Pegboard [85], Montreal Cognitive Assessment [69], and Neuropsychological
Impairment Scale [86]. Due to the multifaceted impact of HIV on neurocognitive functioning,
simple and effective instruments to measure NCI are preferred. The 95-item Neuropsychological
Impairment Scale, for example, has been used to monitor NCI in a variety of patients including
PLWHA [19, 43, 86].
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RESEARCH DESIGN
Study participants and procedures
From June to October 2012, a convenience sample of 361 HIV-infected MSM and TGW
in Lima, Peru were recruited to participate in a cross-sectional survey to examine HIV treatment
outcomes. Eligible participants were ≥18 years, born male and diagnosed with HIV≥1 year. Data
analyses were restricted to 313 eligible participants who were prescribed ART for ≥1 month.
Recruitment occurred at three HIV clinical sites in Lima: 1) Asociación Civil Impacta Salud y
Educación (IMPACTA) 2) Via Libre and 3) Hospital 2 de Mayo. The first two sites are NGOs
that provide HIV/AIDS-related medical care and promote HIV/AIDS awareness throughout the
city, while the third is a public hospital with outpatient clinics. After clinical care visits,
participants meeting eligibility requirements were approached by clinical staff; no participants
refused study participation. Supplemental recruitment occurred via internet-based advertisements
and flyers posted in clinics. After providing written informed consent, participants completed a
60-minute computer-assisted self-administered interview (CASI) and were paid 25 Peruvian
Nuevos Soles (~$10 US) for their time and travel expenses.
Ethics Statement
Ethical oversight was provided by the Institutional Review Boards of IMPACTA, Via
Libre, Hospital 2 de Mayo, and Yale University.
Survey Content and Variable Definitions
NCI was assessed using the standardized 95-item Neuropsychological Impairment Scale
(NIS; Western Psychological Services, Torrance, CA), which is a self-report measure developed
as a quick and convenient way to help elicit diagnostically relevant information about both
general NCI and specific symptom areas (i.e. attention, memory, linguistic functioning, etc.).
Because this scale had not been previously validated in Spanish and in the Peruvian context, we
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first translated and back-translated the scale and tested the wording for meaning [87]. We then
conducted an exploratory factor analysis (EFA) to optimize the scale for use with HIV-infected
MSM and TGW in Peru. The revised 42-item, 8-factor NIS includes a diverse set of factors with
excellent overall reliability (α=0.94; Table 2). Factors include Global Impairment (e.g., “My
reactions are slow” and “I have trouble remembering”), Memory-related (e.g., “I forget where I
put things” and “I am forgetful”), Frustration tolerance-related (e.g., “I feel easily annoyed and
irritable”), Psychomotor/perception-related (e.g., “Part of my body is paralyzed”), Learningrelated (e.g., “Doing simple math problems in my head is difficult”), Language-related (e.g.,
“My speech has become worse”), Pain-associated (e.g., “I have severe headaches”), and
Attention-related (e.g., “I am easily distracted”). The reliability of the 8 factors ranged from
excellent to good (by factor: F1 α=0.92; F2 α=0.84; F3 α=0.83; F4 α=0.69; F5 α=0.75; F6
α=0.77; and F7 α=0.67). All the subscales were analyzed as continuous variables, with higher
score as an indication of higher degree of NCI. The findings from the EFA are found in the
supplementary table.
The primary outcome, adherence, was assessed by self-report using a validated visual
analog scale (VAS) [78]. Other independent facilitators and barriers associated with adherence
were derived from the literature and included demographics, clinical and social characteristics,
education, income, and self-reported sexual identity and orientation. Screening for AUDs was
done using the World Health Organization’s validated 10-item Alcohol Use Disorders
Identification Test (AUDIT) [88], with standard cut-offs associated with any AUD (score≥8) and
alcohol dependence (score≥20). Health Literacy was measured continuously using the Short Test
of Functional Health Literacy in Adults (STOHFLA), a 4-item, self-report scale with scores ≥2
indicating health literacy problems [89]. Past 12-month drug use was self-reported and addiction
severity was measured using the 10-item Drug Abuse Screening Test (DAST-10), with bivariate
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cutoffs of >2 for moderate to severe addiction [90]. Depressive symptoms were measured using
the 10-item Center for Epidemiologic Studies Depression Scale (CES-D 10) with scores >7
indicating moderate to severe depressive symptoms [91].
The study also included ART adherence facilitators. Participants were asked to identify
any cue or reminder, from a list of 9, that they regularly used to aid them with medication-taking
– including reminders from friends, association with routine activities, alarm clocks and
calendars, and locating medications in highly visible places. A summary variable that included
none, a single type of reminder or the use of multiple reminders was created to examine the
extent to which reminders facilitated adherence.
All standardized measures used have previously been translated and validated in Spanish
with the exception of the NIS, which was translated to Spanish and then back-translated into
English to ensure accuracy using previously described methods [92]. Pilot testing with PLWHA
in Lima was conducted prior to the main study to further ensure survey comprehension.
Analyses
Statistical analyses were performed using SPSS (Version 20). The dependent variable,
optimal adherence, was defined by self-report as having taken ≥90% of prescribed ART in the
previous month. Based on prior studies, this cut-off is associated with high-level ART adherence
and plasma viral suppression [93], although more recent studies of more contemporary ART
regimens suggest that ART adherence levels of 85% or higher are associated with viral
suppression [94, 95]. Bivariate associations between all clinically relevant covariates and the
dependent variable were analyzed using chi-square and t-tests for categorical and continuous
variables, respectively. Three analytic approaches were deployed. Covariates with p<0.20 in the
bivariate analysis were incorporated into a multivariate logistic regression model. Additionally,
stepwise forward and backward elimination regression models were conducted; all generated
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similar findings. The final backward elimination model was selected by goodness-of-fit, using
log likelihood criteria. For variables significant in the bivariate analysis but no longer remaining
significant in the final model, we tested for collinearity using the Variance Inflation Factor (VIF)
test.
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RESULTS
Description of the study sample
Table 1 displays the characteristics of the participants, who were mostly in their midthirties (mean=34.3 years), had completed secondary school (69.1%), earned more than minimal
wage (57.8%) and were employed full-time (51.9%). TGW constituted 6.6% of our sample and
78.3% of our sample self-identified as “gay”. Optimal (≥90%) and perfect (100%) ART
adherence was self-reported by 85.9% and 54.5%, respectively. Substance use disorders were
prevalent with 41.7% meeting screening criteria for an AUD (AUDIT ≥8) and 10.5% reporting
recreational drug use; 42.5% met criteria for moderate to major depressive symptoms. The
average score for the Global Impairment was 8.8 ±7.7. Table 2 describes the descriptive statistics
for the revised NIS and the supplementary table summarizes our new factor analysis of the NIS.
Correlates of ART adherence
Table 3 highlights factors significantly associated with optimal ART adherence. In the
bivariate analysis, several factors were significantly (p<0.05) and negatively associated with
adherence, including having an AUD, identifying as TGW, having health literacy issues,
depressive symptoms and greater impairment within the following NIS subtest domains: 1)
Frustration Tolerance; and 2) Psychomotor. Higher income was positively associated with
optimal adherence.
We also examined the study participants’ use of different types of medication-taking
reminders, which were correlated with both NCI and adherence in bivariate analyses. Significant
collinearity associations were not found between areas of NCI and the presence of various
medication-taking reminders (data not shown). Individuals with greater impairment within the
NIS subtest for Memory showed stronger associations with using an alarm clock and putting
their medications within their sight.
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After controlling for variables significant in the bivariate analysis, multivariate modeling
confirmed that several factors were independently associated with optimal ART adherence.
Participants with higher levels of Psychomotor impairment (AOR=0.534; 95% CI=0.317-0.931)
and those that met criteria for an AUD (AOR=0.203; 95% CI=0.063–0.655) were nearly 2 times
and 5 times less likely to be optimally adherent to ART, respectively. Individuals that selfidentified as TGW (AOR=0.175 95% CI=0.032-0.954) and those with health literacy issues
(AOR=0.253 95% CI=0.077-0.831) were nearly 6 times and 4 times less likely to be optimally
adherent to ART, respectively. In contrast, participants earning higher incomes, specifically
minimal wage or greater, were 3 times more likely to be optimally adherent (AOR=3.037; 95%
CI=1.016-9.081). ART adherence reminders however, did not influence the final model
outcomes.

29

DISCUSSION
To our knowledge, aside from one study using global NCI measures in PLWHA in Peru
(29), this is the first study investigating the extent and subscale assessment of NCI in Peru and
their associations with ART adherence among HIV-infected MSM and TGW. Here we find that
the Psychomotor NCI subdomain was significantly associated with suboptimal ART adherence
[96]. A recent meta-analysis of 207 studies from low-to-middle income countries identified
factors associated with non-adherence after controlling for study design and country income
level and, like our study, both substance use disorders and financial constraints were associated
with non-adherence. This meta-analysis, however, did not include NCI [97].
Despite the identification of HIV-associated NCI more than 25 years ago, the
pathophysiology of HIV-mediated neuronal cell death has yet to be fully characterized [98] [10,
99]. CNS inflammation and immune activation are one of the earliest signs of CNS injury in HIV
(37). Neurological images have shown evidence of brain atrophy [100], disruptions in brain
connectivity networks [101], and reduced cerebral blood flow [102] within the first year of
infection. Today, acute neurocognitive decline is less prevalent as severe forms of NCI have
been greatly reduced since ART introduction, especially at higher CD4 counts [103, 104]. NCI
symptoms, as suggested in our study, continue to persist with mild to moderate symptoms, which
are often under-recognized [105], yet contribute to poor outcomes. For example, one study found
that among PLWHA with undetectable viral loads, 27% self-reported cognitive complaints but
upon further examination, 74% of the study participants met NCI criteria, including 64% of
participants without complaints [106].
Though other studies have documented NCI during early stage HIV infection [107], HIVassociated NCI is particularly concerning because it typically worsens with advancing HIV
progression [108]. Given that NCI disrupts several cognitive domains such as memory, learning
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ability, attention and executive functioning [19], we speculated that many of these factors could
pose significant barriers to a patient’s ability to take prescribed ART medications. Previous
studies among individuals with substance use disorders (SUDs) have found that NCI, in addition
to the complexity of a medication regimen, was predictive of lower adherence [6]. One study in
PLWHA found that deficits in executive function, memory, and attention domains are most
closely associated with poor adherence [27]. Older, HIV-infected adults are particularly
vulnerable, since increasing age is an additional risk factor that independently causes cognitive
decline and dementia [109-111]. In terms of medication adherence, older adults have
traditionally had higher levels of adherence, but nonetheless, the negative impact of NCI on
medication adherence has also been confirmed in older patients [14]. It is worth considering the
existence of a self-destructive, bidirectional, vicious cycle between NCI and suboptimal
medication adherence: impaired cognitive function may hamper adherence just as sub-optimal
adherence may contribute to NCI. Therefore, optimal adherence is predicated on the argument
that there is sound functioning across the aforementioned cognitive domains [19]. Patients must
be cognizant of their condition, remember to take their medications, and do so according to
instructions. In the context of neurocognitively-impaired patients, having optimal ART
adherence is not only essential for ideal HIV treatment, but also a mean to significantly reduce
NCI symptoms. For example, one study found that, after 6 and 15 months of ART, the
proportion of subjects with poor neuropsychological scores decreased over time from 81% at
baseline to 50% and 22%, respectively. This finding suggests that NCI symptoms, if present,
would in turn contribute to better ART adherence [71].
The revised NIS measures several NCI subscales designed to quantify various cognitive
domains commonly affected by HIV. In a previous study, mean levels of general cognitive
impairment, known as the Global Impairment, were associated with suboptimal ART adherence
31

on the bivariate level, but not in the final model [96]. In the latest analyses presented here, we
conducted a factor analysis to optimize the scale for HIV-infected MSM and TGW in Peru. The
revised 42-item, 8-factor NIS includes a diverse set of factors with excellent overall reliability
(α=0.94; Supplementary Table). Factors include: Global Impairment, Memory, Frustration
Tolerance, Psychomotor, Learning, Language, Pain, and Attention. Each of these subscales is
straightforward in its ability to identify key cognitive issues. To our knowledge, this is the first
revision to the NIS for our study population in Peru. Although some of the NIS subscales were
significant in the bivariate model, the Psychomotor subscale was the only subscale that remained
significant in the multivariate model, reflecting difficulties in taking medications due to physical
disabilities. Nurses and physicians should be more aware of their patients’ physical and mental
states when prescribing ART, and offer solutions that will maximize adherence. It is also worth
noting that Frustration Tolerance approached significance in the multivariate model, which may
suggest that individuals with NCI suffer from decreased patience and increased irritability.
Moderate to severe levels of depressive symptoms were highly prevalent (42.5%) and did
not remain independently correlated with suboptimal adherence in the final model, despite
depression not being collinear with NCI or AUDs as has been shown elsewhere [112, 113].
Previous studies have documented that depressive symptoms are highly correlated with ART
non-adherence [114, 115], including in low- and middle-income countries [116], but these
studies did not address NCI. Until prospective studies disentangle the relationship between
depressive symptoms, AUDs and NCI, it would be worthwhile for treatment providers to screen
for and treat each disorder to optimize HIV treatment outcomes. This is particularly relevant as
each disorder is under-diagnosed in clinical care settings [117-120], remains inadequately treated
[64, 121, 122] yet amenable to effective treatment interventions [123].
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Though AUDs have been previously associated with ART non-adherence among HIVinfected MSM and TGW in Peru [96], findings here from a larger sample size of patients who
were continuously on ART for at least one month re-confirm this association as has been
described elsewhere [58, 124, 125] and extends to findings to include more specific aspects of
NCI. Many other factors contribute to NCI, including drug and AUDs [103, 104]. The high
prevalence of AUDs in this sample, similar to reported elsewhere in Latin America, exist partly
due to cultural and sexual biases in vulnerable and marginalized MSM communities [126].
Outside of the context of HIV, AUDs cause harm through alcohol-related liver toxicity [127,
128] and poor decision-making [129].
Earning higher income was independently associated with optimal ART adherence.
Though ART is provided free in Peru, the 94 (30%) participants earning less than minimal wage
may be a surrogate for some other non-measured variable like food insecurity and limited
transportation to renew ART, which has been associated with non-adherence in other settings
where ART was provided for free [130, 131]. Although only 20 individuals self-identified as
TGW (6.6%), our multivariate model shows that these individuals were almost 6 times as likely
to have suboptimal adherence to ART. These further confirm other reports indicating that, within
the HIV epidemic, TGW represent a highly vulnerable community that does not meet HIV
standard-of-care and suffers from issues with risk perception and HIV care accessibility [132134]. Low health literacy was independently associated with suboptimal ART adherence.
Neurocognitive impairment hinders basic knowledge, such as numeracy, and critical-thinking
skills, such as comprehension and application of healthcare information [135]. These findings
support the need to explore new methods of informing patients of their conditions and details
regarding their treatment, such as technology and interventions [136, 137].
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While our findings examined adherence barriers, we also sought to explore adherence
facilitators like medication reminders that might be used to overcome problematic adherence in
other settings [138]. Though guidelines from the International Association of Physicians in AIDS
Care do, in general, recommend the use or reminders to improve adherence, there is insufficient
data to support their use in patients with underlying SUDs [139], with recommendations to
further examine their use in this special population, especially since over 40% of our sample had
an AUD. It is noteworthy that low-cost mobile technologies are gaining traction to improve
adherence in a number of emerging settings and patient populations. Recent studies show that
Peruvian PLWHA, including MSM and TGW, not only have access to mobile health
technologies, but are interested in using them to improve health [140, 141]. These are pertinent
findings since mobile technology offers a cost-effective method for accessing a larger proportion
[142] with reminder options, and potentially to improve ART adherence [141, 143, 144]. Despite
these promising results, it is unclear whether technology use will be hindered by various levels of
NCI and the negative association between high levels of impairment in the Psychomotor domain
and ART adherence among our sample [145]. Future intervention development will require
carefully tailoring and testing among a spectrum of NCI for both content and delivery for HIVinfected Peruvian MSM and TGW.
Study Limitations
Our work included some inherent methodological limitations. First, causality cannot be
determined because of the cross-sectional nature of this study. Second, while other factors
associated with non-adherence (like pill burden, dosing frequency, and lifestyle changes) were
not included, few first-line ART regimens are available in Peru and they do not allow sufficient
variability in the regimen. Third, sampling bias may have occurred, since study participants were
recruited from only three clinics in Lima, but these are among the largest clinics providing HIV
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services to MSM and TGW. Social desirability bias may also have played a role in reporting of
sensitive issues like stigma or alcohol use, although the use of CASI usually reduces this bias
[146-148]. Fourth, the revised NIS has not been validated in Peru, although another other revised
NIS study has recently been published [149]. Although the NIS features specific categorizations
of severity, it only has validated normative scores for the US population [86]. Since our Peruvian
MSM and TGW cohort has never been analyzed with respect to NCI, we conducted a new factor
analysis to refine the instrument. Prospective studies with a larger sample size may help reduce
these limitations. Fifth, there are inherent limitations to using VAS to measure self-reported ART
adherence. This method has been cited to cause over-reporting bias [150] and may not be as
effective as other methods, such as pharmacy refill or MEMS [81, 151]. Lastly, the 90% cutoff
used in this study may not have been precise and future studies could explore more robust
measurements.
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CONCLUSION
This study is the first to describe the magnitude and impact of NCI on ART adherence
among HIV-infected MSM and TGW in Lima, Peru. Though drug use, AUDs, depression and
NCI were prevalent in the population prescribed ART, only the presence of AUDs, increasing
levels of psychomotor NCI, self-identifying as a TGW, and health literacy issues were associated
with suboptimal ART adherence. Future studies that incorporate standardized measures of NCI
are crucial to assess their contribution to adherence, but more importantly, to understand how to
intervene when NCI is present, especially through the creation and testing of evidence-based
adherence interventions. The next generation of adherence interventions will need to be more
cost-effective and tailored to the unique need of patients, especially those with NCI. Earlier
initiation of ART at higher CD4 counts, before NCI manifests itself clinically, is also central to
better ART treatment outcomes, since NCI contributes to ART non-adherence.
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